YK01 combined with temozolomide (TMZ) can synergically inhibit glioblastoma multiforme (GBM) growth in vivo. (IMAGE)
Caption
(A) Established primary GBM model using U87-MG cells expressing luciferase. (B) The growth of GBM xenografts was monitored by bioluminescence imaging on day 10, day 14, day 18, and day 22 after tumor implantation. (C) In vivo bioluminescence images and quantification of tumor growth of U87-MG-Luci xenografts treated with TMZ, YK01, or vehicle after tumor implantation. (D) Kaplan-Meier survival analysis of mice bearing U87-MG-Luci xenografts treated with TMZ, YK01, or vehicle. n = 5 for each group. (E) Body weight changes of each group.
Credit
Min Wu, Lin Zhang, Weikai Guo, Shiyi Lv, Wangrui Jin, Shuangshuang Zhu, Huang Chen, Shuyi Jian, Layang Liu, Yajing Xing, Shihong Peng, Mingyao Liu, Yihua Chen, Zhengfang Yi
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. Adaptations must be shared under the same terms.
License
CC BY-NC-SA